循环肿瘤细胞核内AR-V7作为去势抵抗性前列腺癌预测生物标志物的有效性评估
这项盲法相关性研究纳入142例转移性去势抵抗性前列腺癌患者,在二线及以上系统治疗前检测循环肿瘤细胞核内AR-V7蛋白。在高危组中,AR-V7阳性患者接受紫杉烷的总生存优于ARS抑制剂,而AR-V7阴性患者接受ARS抑制剂的总生存优于紫杉烷。
要点
- 高危mCRPC患者中,AR-V7阳性者紫杉烷组中位OS 14.3个月,ARS抑制剂组7.3个月。
- 高危mCRPC患者中,AR-V7阴性者ARS抑制剂组中位OS 19.8个月,紫杉烷组12.8个月。
- 循环肿瘤细胞核内AR-V7蛋白或可帮助选择紫杉烷或ARS抑制剂治疗。
核心结论
- 循环肿瘤细胞核内AR-V7蛋白可识别可能从紫杉烷化疗而非ARS抑制剂治疗中获得更长生存的mCRPC患者。
研究设计与样本
- 盲法相关性研究,2012年12月31日至2016年9月1日,纳入142例组织学确诊的mCRPC患者,来自Memorial Sloan Kettering癌症中心、Royal Marsden和London Health Sciences Centre。
- 在二线或以上系统治疗前采集血样,检测循环肿瘤细胞核内AR-V7蛋白。
主要发现
- 142例患者平均年龄69.5岁(SD 9.6),其中70例被常规预后因素归为高危。
临床怎么用
- 在mCRPC二线及以上治疗前,可考虑检测循环肿瘤细胞核内AR-V7蛋白,辅助选择紫杉烷或ARS抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or taxane is an unmet medical need. OBJECTIVE: To determine whether a validated assay for the nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells can determine differential overall survival among patients with mCRPC treated with taxanes vs ARS inhibitors. DESIGN, SETTING, AND PARTICIPANTS: This blinded correlative study conducted from December 31, 2012, to September 1, 2016, included 142 patients with histologically confirmed mCRPC and who were treated at Memorial Sloan Kettering Cancer Center, The Royal Marsden, or the London Health Sciences Centre. Blood samples were obtained prior to administration of ARS inhibitors or taxanes as a second-line or greater systemic therapy for progressing mCRPC. MAIN OUTCOMES AND MEASURES: Overall survival after treatment with an ARS inhibitor or taxane in relation to pretherapy AR-V7 status. RESULTS: Among the 142 patients in the study (mean [SD] age, 69.5 [9.6] years), 70 were designated as high risk by conventional prognostic factors. In this high-risk group, patients positive for AR-V7 who were treated with taxanes had superior overall survival relative to those treated with ARS inhibitors (median overall survival, 14.3 vs 7.3 months; hazard ratio, 0.62; 95% CI, 0.28-1.39; P = .25). Patients negative for AR-V7 who were treated with ARS inhibitors had superior overall survival relative to those treated with taxanes (median overall survival, 19.8 vs 12.8 months; hazard ratio, 1.67; 95% CI, 1.00-2.81; P = .05). CONCLUSIONS AND RELEVANCE: This study suggests that nuclear-localized AR-V7 protein in circulating tumor cells can identify patients who may live longer with taxane chemotherapy vs ARS inhibitor treatment.
引用
- Scher HI, Graf RP, Schreiber NA, et al. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol. 2018. PMID: 29955787. doi:10.1001/jamaoncol.2018.1621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。